Signet Ring Cell Component, not the Lauren Subtype, Predicts Poor Survival: An Analysis of 198 Cases of Gastric Cancer

References

• International Agency for Research on Cancer . Stomach cancer: estimated incidence, mortality and prevalence worldwide in 2012. WHO, Lyon, France (2018). http://globocan.iarc.fr/old/FactSheets/cancers/stomachnew.asp.
   Google Scholar
• Siegel RL , MillerKD, JemalA. Cancer statistics, 2017. CA Cancer J. Clin.67(1), 7–30 (2017).
   PubMed Web of Science ®Google Scholar
• Tsukuma H , OshimaA, NaraharaH, MoriiT. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut47(5), 618–621 (2000).
   PubMed Web of Science ®Google Scholar
• Smith DD , SchwarzRR, SchwarzRE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J. Clin. Oncol.23(28), 7114–7124 (2005).
   PubMed Web of Science ®Google Scholar
• In H , SolskyI, PalisBet al. Validation of the 8th edition of the AJCC TNM staging system for gastric cancer using the National Cancer Database. Ann. Surg. Oncol.24(12), 3683–3691 (2017).
   PubMed Web of Science ®Google Scholar
• Choi YY , BaeJM, AnJYet al. Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J. Surg. Oncol. 110(2), 129–135 (2014).
   PubMed Web of Science ®Google Scholar
• Zhu L , LiZ, WangY, ZhangC, LiuY, QuX. Microsatellite instability and survival in gastric cancer: a systematic review and meta-analysis. Mol. Clin. Oncol.6(3), 699–705 (2015).
   Google Scholar
• Cho J , KangMS, KimKM. Epstein–Barr virus-associated gastric carcinoma and specific features of the accompanying immune response. J. Gastric Cancer16(1), 1–7 (2016).
   PubMed Web of Science ®Google Scholar
• Sohn BH , HwangJE, JangHJet al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin. Cancer Res23(15), 4441–4449 (2017).
   PubMed Web of Science ®Google Scholar
• Lauren P . The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand.64, 31–49 (1965).
   PubMedGoogle Scholar
• Junli MA , HongS, LindaK, ShanZ. Lauren classifiction and individualized chemotherapy in gastric cancer. Oncol. Lett.11(5), 2959–2964 (2016).
   PubMed Web of Science ®Google Scholar
• Al-Batran SE , HofheinzRD, PauligkCet al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the Phase II part of a multicentre, open-label, randomised Phase II/III trial. Lancet Oncol.17(12), 1697–1708 (2016).
   PubMed Web of Science ®Google Scholar
• Tan IB , IvanovaT, LimKHet al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology141(2), 476–485 (2011).
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer Association . Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer14, 101–112 (2011).
   PubMed Web of Science ®Google Scholar
• Bosman FT , CarneiroF, HrubanRH, TheiseND. WHO Classification of Tumours of the Digestive System (4th Edition). WHO, Geneva, Switzerland, 417 (2010).
   Google Scholar
• Al-Batran SE , PauligkC, HomannNet al. LBA27_PR docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: updated results from multicenter, randomized Phase III FLOT4-AIO trial (German Gastric Group at AIO). Ann. Oncol.28(Suppl. 5), v605–v649 (2017).
   Google Scholar
• Zhang X , ChenX, WuT, ZhangY, YanK, SunX. Modified Glasgow Prognostic Score as a prognostic factor in gastric cancer patients: a systematic review and meta-analysis. Int. J. Clin. Exp. Med.8(9), 15222–15229 (2015).
   PubMed Web of Science ®Google Scholar
• Colosimo EA , GioloSR. Análise de sobrevivência aplicada (1st Edition). Edgard Blucher, São Paulo, Brazil, 392 (2006).
   Google Scholar
• Faraggi D , SimonR. A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Stat. Med.15(20), 2203–2213 (1996).
   PubMed Web of Science ®Google Scholar
• Verweij PJ , Van HouwelingenHC. Cross-validation in survival analysis. Stat. Med. 12(24), 2305–2314 (1993).
   PubMed Web of Science ®Google Scholar
• R Core Team. A language and environment for statistical computing . Vienna, Austria. R Foundation for Statistical Computing (2017). www.R-project.org/.
   Google Scholar
• Henson DE , DittusC, YounesM, NguyenH, Albores-SaavedraJ. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch. Pathol. Lab. Med.128(7), 765–770 (2004).
   PubMed Web of Science ®Google Scholar
• Ming SC . Gastric carcinoma: a pathobiologial classification. Cancer39(6), 2475–2485 (1977).
   PubMed Web of Science ®Google Scholar
• Pernot S , VoronT, PerkinsG, Lagorce-PagesC, BergerA, TaiebJ. Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge. World J. Gastroenterol.21(40), 11428–11438 (2015).
   PubMed Web of Science ®Google Scholar
• Kwon KJ , ShimKN, SongEMet al. Clinicipathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Gastric Cancer17(1), 43–53 (2014).
   PubMed Web of Science ®Google Scholar
• Chon HJ , HyungWJ, KimCet al. Differential prognosis implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Ann. Surg.265(5), 946–953 (2017).
   PubMed Web of Science ®Google Scholar
• Bamboat ZM , TangLH, VinuelaEet al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann. Surg. Oncol.21(5), 1678–1685 (2014).
   PubMed Web of Science ®Google Scholar
• Cunningham D , StarlingN, RaoSet al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med.358(1), 36–46 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Batran SE , HartmannJT, HofheinzRet al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a Phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann. Oncol.19(11), 1882–1887 (2008).
   PubMed Web of Science ®Google Scholar
• Waddell T , ChauI, CunninghamDet al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label Phase III trial. Lancet Oncol.14(6), 481–489 (2013).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , MoiseyenkoVM, TijulandinSet al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J. Clin. Oncol.24, 4991–4997 (2006).
   PubMed Web of Science ®Google Scholar
• Cats A , JansenEPM, van GriekenNCTet al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomized Phase III trial. Lancet Oncol.19(5), 616–628 (2018).
   PubMed Web of Science ®Google Scholar
• Park SH , SohnTS, LeeJet al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, including survival and subset analyses. J. Clin. Oncol.33(28), 3130–3136 (2015).
   PubMed Web of Science ®Google Scholar
• MacDonald JS , SmalleySR, BenedettiJet al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med.345(10), 725–730 (2001).
   PubMed Web of Science ®Google Scholar
• Lin D , LiY, XuHet al. Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes. Am. J. Clin. Oncol.36(4), 325–330 (2013).
   PubMed Web of Science ®Google Scholar
• Marchet A , MocellinS, AmbrosiAet al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann. Surg.245(4), 543–552 (2007).
   PubMed Web of Science ®Google Scholar
• Jiang X , HikiN, NunobeSet al. Prognostic importance of the inflammation-based Glasgow Prognostic Score in patients with gastric cancer. Br. J. Cancer107(2), 275–279 (2012).
   PubMed Web of Science ®Google Scholar